Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 8:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,781 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation, U2AF1 Gene Mutation, SRSF2 Gene Mutation
Interventions
Recommendation for treatment with immunotherapy
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab
Biological · Other
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Iowa City, Iowa + 8 more
Conditions
Advanced Hepatocellular Carcinoma, Advanced Melanoma, Locally Advanced Melanoma, Metastatic Melanoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cholecalciferol, Computed Tomography, Desloratadine, Immunotherapy, Infusion Procedure, Magnesium Sulfate, Magnetic Resonance Imaging, Propranolol
Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Lung Cancer
Interventions
High-Intensity Interval Training (HIIT), Moderate-Intensity Continuous Training (MICT)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma
Interventions
Observational study with no interventions
Other
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
La Jolla, California
Conditions
Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pleural Malignant Mesothelioma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Pleural Malignant Mesothelioma AJCC v7, WT1 Positive
Interventions
Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
Biological · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Leukemia, Acute Lymphoblastic, Lymphoblastic Leukemia, Acute, Childhood
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 25 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
OncoPrism-HNSCC™
Diagnostic Test
Lead sponsor
Cofactor Genomics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Relapsed/Refractory Aggressive B-Cell Malignancies
Interventions
ONCT-808, Bridging Therapy
Biological · Drug
Lead sponsor
Oncternal Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Duarte, California • Boston, Massachusetts • Houston, Texas
Terminated Phase 1Phase 2 Interventional Results available

CMP-001 for Relapsed and Refractory Lymphoma

NCT03983668
Conditions
Lymphoma
Interventions
CMP-001, Pembrolizumab
Drug
Lead sponsor
Umar Farooq
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma
Interventions
Tarlatamab, Sacituzumab Govitecan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Ewing's Sarcoma, Rhabdomyosarcoma
Interventions
therapeutic autologous dendritic cells, indinavir sulfate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 35 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Non-Small Cell Lung Cancer, Metastatic Lung Cancer
Interventions
Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Conditions
Advanced Renal Cell Carcinoma
Interventions
Carevive software
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Rochester, New York
Conditions
Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, ColoRectal Cancer, Gastric Cancer, Esophageal Cancer, HepatoCellular Carcinoma
Interventions
INO-1400, INO-9012, INO-1401
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Detroit, Michigan • Rochester, Minnesota • Chapel Hill, North Carolina + 2 more
Conditions
Solid Tumor
Interventions
23ME-01473
Drug
Lead sponsor
23andMe, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Grand Rapids, Michigan • Portland, Oregon • San Antonio, Texas
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
18
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Park Ridge, Illinois + 12 more
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
AMG 701, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
17
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 12 more
Completed Phase 1Phase 2 Interventional Results available

Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

NCT00923910
Conditions
Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL), Leukemia, Chronic Myelogenous (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL)
Interventions
WT1 Peptide-Pulsed Dendritic Cells, Donor Lymphocytes, IL-4, KLH, WT1 Peptides, Endotoxin, Diphenhydramine, Acetaminophen
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 74 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Early Phase 1 Interventional Results available

Bronchoscopic Cryo-Immunotherapy of Lung Cancer

NCT04049474
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
22 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma
Interventions
Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Endometrial Cancer
Interventions
Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib, Talazoparib, Trastuzumab emtansine, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, Letrozole, Giredestrant, Abemaciclib
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Duarte, California • San Francisco, California • Washington D.C., District of Columbia + 18 more
Conditions
Tumor, Cardiovascular
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas